How many new drugs does the FDA approve each year?

Quick answer: The FDA approved 46 novel drugs in 2026 through October 9. That already matches all of 2025 (46) and is close to the 2016 to 2025 average of about 47 a year, with nearly three months still to go. The recent high was 59 in 2018.

The short version

• About 47 a year. From 2016 to 2025, the FDA approved 466 novel drugs, about 47 a year (our math).
• 2026 is on a strong pace. It hit 46 by October 9, so it will likely end above average.
• Half are for rare diseases. In 2025, 23 of the 46 approvals were for rare conditions.
• A count is not a scorecard. One approval might help millions, another a few hundred. Both count as one.

What the FDA means by a "novel drug"

The FDA’s definition is simple: novel drugs are "new drugs never before approved or marketed in the U.S."

That rules out a lot. A new generic of an old drug doesn’t count. Neither does a new dose, a new pill form, or an old drug approved for a new use. Each novel drug is a new active ingredient American doctors couldn’t prescribe before.

That’s why Wegovy and Zepbound aren’t on these lists. They use the same ingredients as Ozempic and Mounjaro, which were counted when they were first approved.

One more detail: these counts come from the FDA’s drug center, called CDER. Vaccines and cell and gene therapies go through a different FDA center, so they aren’t in these numbers.

Novel drugs you’ve probably heard of

Most novel drugs never become household names. A few do. Here are some from the years on the chart:

A few of these opened whole new chapters. Semaglutide and tirzepatide led to the weight-loss versions millions of people now take. Rezdiffra was the first drug approved for its liver condition. Journavx gave doctors a new kind of pain reliever that isn’t an opioid.

Why so many new drugs now?

There’s no single reason. A few things have stacked up over the past few decades.

Better science. Mapping the human genome helped researchers find the exact genes and proteins behind many diseases. That gave them clearer targets to aim drugs at. Many newer drugs are antibodies or other biologics built to hit one specific target.

Rewards for rare-disease drugs. Since 1983, the Orphan Drug Act has given companies extra incentives to develop drugs for rare conditions. That’s a big reason half of recent approvals are for rare diseases.

Faster review paths. The FDA has several programs to speed up drugs for serious conditions, including "breakthrough therapy" status, added in 2012. In 2025, 72% of novel approvals used at least one of these programs.

And AI? It’s starting to matter, but it hasn’t driven these numbers yet. Drugs take 10 years or more to develop, so today’s approvals mostly come from research that started before modern AI tools existed.

Where AI is showing up:

• Finding and designing drugs. One of the furthest along is rentosertib, a drug for a lung-scarring disease called idiopathic pulmonary fibrosis. AI helped pick its target and design the molecule. It moved into a large final-stage trial in 2026, and approval is still years away.
• Inside the FDA. In June 2025, the FDA rolled out an AI tool called Elsa that helps staff read, write and summarize. The agency says it’s used to speed up parts of scientific reviews. People still make the approval decisions.

2026 isn’t over yet

The 2026 bar shows approvals through October 9 only. The other bars are full years.

So 2026 isn’t "average." It reached the average with nearly three months left. If the pace so far holds, it could end in the high 50s, close to the 2018 high. That’s a rough projection, not a promise.

We’ll update this page once the FDA posts the final 2026 count.

Why more approvals matter for patients

A new approval means a new option. For a lot of people, that matters less as a statistic and more as a choice their doctor didn’t have last year.

This counts most for people with serious or rare diseases. For some rare conditions, a new approval is the first treatment ever available. In the FDA’s 2025 report, 43% of novel drugs were "first in class," meaning they work in a new way. And 70% were approved in the US before anywhere else.

What the count doesn’t tell you

A higher number isn’t automatically better news. Approval counts can’t show:

• How well each drug works. Some are big steps forward. Others offer a small gain over what already exists.
• How many people it helps. One approval might help millions. Another might help a few hundred.
• Price or access. An approved drug can still be hard to get if it costs a lot or insurance won’t cover it.
• Long-term safety. Approval means the FDA found the benefits outweigh the known risks for the intended use. Doctors keep learning about a drug for years after that.

So a year with 37 approvals could hold more real progress than a year with 55.

What this means for longevity

No drug is approved to treat aging itself. The FDA approves drugs for specific diseases, and aging isn’t on that list.

But many new drugs go after the conditions that cut lives short or take years of good health away:

• Heart and metabolism. Drugs like semaglutide and tirzepatide changed how doctors treat diabetes and weight. In 2024, the FDA also approved semaglutide (as Wegovy) to lower the risk of heart attack and stroke in some adults with heart disease and excess weight. Leqvio added a new way to lower LDL cholesterol.
• The brain. Leqembi and Kisunla can modestly slow memory decline in early Alzheimer’s. They’re not cures, but they act on the disease itself, not just the symptoms.
• The liver. Rezdiffra treats a serious form of fatty liver disease, a condition tied closely to weight and blood sugar.

That’s how longer lives have usually been won. Not through one miracle drug, but through steady progress against heart disease, cancer, infections and more. It’s a big part of why Americans live decades longer than they did a century ago.

New drugs are one half of the story. The other half is finding problems early, when treatment works best. That starts with your regular doctor and routine checks. If you want to go further, find longevity care near you that can add to that care.

Medical progress gives us more tools every year. Catching problems early is how those tools turn into more healthy years.